Psychedelic Assisted Therapy with DMT: Michelle Baker-Jones & Dr Graham Campbell Discuss the Experience of a Phase I Trial (LONDON & LIVESTREAM)

Depression presents a serious challenge to individuals, societies, and health services. There is a need for new approaches to the treatment of depression, as many people don’t find benefit from antidepressants and standard psychological therapy.  

Psychedelic therapy trial outcomes with psilocybin have been encouraging. This lends hope for the investigation of N,N-Dimethyltryptamine (DMT), a traditional psychedelic drug strongly related to psilocybin but with a much shorter psychedelic experience.

DMT exists in nature across the plant and animal kingdoms. It is a simple tryptamine, similar to the neurotransmitter serotonin. Studies with DMT have shown it to increase global integration of brain networks and induce neuroplasticity; brain changes that could underpin therapeutic benefit for people with depression.  

To assess the therapeutic potential of DMT, Small Pharma is leading the world’s first DMT clinical trial for depression, in collaboration with Imperial College London. 

The Phase I study was conducted as a double-blind, randomised, placebo-controlled study of a single, ascending intravenous dose of DMT with the primary goal of assessing safety and tolerability in psychedelic-naïve healthy subjects. The Phase IIa trial, exploring the efficacy of psychedelic-assisted therapy with DMT for people with moderate to severe depression, is currently in progress.

Join Michelle Baker-Jones and Dr Graham Campbell (Lead Therapist and Study Psychiatrist for the Phase I/IIa trials) for this exclusive event, as they give a brief overview of this early trial and provide us with insight into the trial setting, the participants and their approach to psychedelic therapy with DMT. They will also share details of the participant journey through the trial and the broad nature of their experiences.

WHEN: 18:00 - 22:30 on Tuesday 21st June, the bar will remain open until 10.30pm for socialising after the talk

WHERE: The Cockpit Theatre, Gateforth Street, London, UK

The event will also be available via live stream.

SCHEDULE:

18:00 - 18:55   Registration + Bar open

19:00 - 19:10   Welcome from the Psychedelic Society

19:10 - 20:00  TALK >> DMT For Depression: Michelle Baker-Jones & Dr Graham Campbell Discuss the Experience of a Phase I Trial

20:00 - 21:00   Q&As

21:00 - 22:30   Bar open

SPEAKERS
Michelle Baker-Jones

Michelle is an integrative psychotherapeutic counsellor in private practice, based in London. She has been a member of Imperial College's psychedelic research team since 2015. Michelle was a lead guide on the Imperial College’s most recent RCT trial which is comparing psilocybin to antidepressants as a form of treatment for depression (Psilodep2). Currently she is working on a DMT trial as the lead therapist looking at the efficacy of DMT to treat depression, a collaborative trial between Small Pharma and Imperial College. Michelle offers individual psychedelic integration for people who are struggling to process psychedelic experiences and cofacilitates two monthly Psychedelic Integration groups.

Dr Graham Campbell

Dr Graham Campbell worked in NHS mental health services for 15 years; 8 of those years as a consultant psychiatrist on an inpatient ward in Brighton & Hove. He has a Masters degree in Neuroscience from Kings College London and trained with the Imperial College Psychedelic Research team to work as an assistant guide on the psilocybin vs escitalopram depression trial.

He has helped to organise and facilitate psychedelic integration groups in Brighton since 2019 and has worked as an associate editor for a special edition of Frontiers in Psychiatry on the potential clinical application of psychedelics. He is a member of the Advisory Council with The Institute of Psychedelic Therapy (IPT) and chairs Academic Circle groups for IPT members/affiliates.
In 2020, he left the NHS to work full-time as the Study Psychiatrist for a trial investigating N,N-dimethyltryptamine (DMT) as a potential treatment for Major Depressive Disorder. This trial is a collaboration between Imperial College and Small Pharma Ltd and is being conducted at Hammersmith Medicines Research (HMR) in London. Phase I of the trial, with healthy volunteers, has been completed, with Phase IIa currently underway.

Graham also writes visualisation scripts for Lumenate, a psychedelic meditation app, and often bangs on about electronic music.
 

REFUNDS POLICY: Please note, we do not arrange refunds or exchanges. When possible we encourage reselling on Ticketswap.

ACCESS:  We do our best to include everyone in our events, regardless of health circumstances. If you have access requirements please email the event organiser directly to discuss. Many facilitators are able to offer reduced ticket prices for those truly unable to afford the ticket price. If this applies to you, do please get in touch with the event organiser.

For PSYCHEDELIC KNOWLEDGE AND RESOURCES please check out the Psychedelic Society website. 

Our facilitators have agreed to our code of conduct. Learn about our procedure for raising concerns

MEMBERS of the Psychedelic Society get a discount off almost all of our events.
Join from £5 a month and become part of this amazing community with invites to special events and more.